

# Anne Katrin Schlag

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8174042/publications.pdf>

Version: 2024-02-01

19  
papers

644  
citations

687220

13  
h-index

839398

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

611  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. <i>Lancet Psychiatry</i> , 2017, 4, 419-426.	3.7	127
2	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. <i>Journal of Psychopharmacology</i> , 2022, 36, 258-272.	2.0	103
3	Europeans and aquaculture: perceived differences between wild and farmed fish. <i>British Food Journal</i> , 2013, 115, 209-222.	1.6	59
4	Aquaculture: an emerging issue for public concern. <i>Journal of Risk Research</i> , 2010, 13, 829-844.	1.4	57
5	A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. <i>International Journal of Drug Policy</i> , 2018, 56, 144-152.	1.6	44
6	Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics. <i>Neuropharmacology</i> , 2021, 191, 108586.	2.0	42
7	So near yet so far: why won't the UK prescribe medical cannabis?. <i>BMJ Open</i> , 2020, 10, e038687.	0.8	36
8	An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK?. <i>Medical Cannabis and Cannabinoids</i> , 2020, 3, 76-83.	1.2	34
9	Medical cannabis in the UK: From principle to practice. <i>Journal of Psychopharmacology</i> , 2020, 34, 931-937.	2.0	27
10	Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21. <i>Psychopharmacology</i> , 2022, 239, 1147-1155.	1.5	25
11	Percentages of problem drug use and their implications for policy making: A review of the literature. <i>Drug Science, Policy and Law</i> , 2020, 6, 205032452090454.	0.6	24
12	Cannabis based medicines and cannabis dependence: A critical review of issues and evidence. <i>Journal of Psychopharmacology</i> , 2021, 35, 773-785.	2.0	22
13	Risk-risk tradeoffs: what should we do in Europe?. <i>Journal of Risk Research</i> , 2017, 20, 963-983.	1.4	14
14	Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21. <i>Frontiers in Pain Research</i> , 0, 3, .	0.9	9
15	A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use. <i>International Journal of Drug Policy</i> , 2021, 91, 103180.	1.6	8
16	Medical cannabis and epilepsy in the UK – A qualitative analysis of the carers' perspective: 'We're asking for quality of life for our children'. <i>Drug Science, Policy and Law</i> , 2021, 7, 205032452110349.	0.6	5
17	Looking back and going forward: what should the new European Commission do in order to promote evidence-based policy-making?. <i>Journal of Risk Research</i> , 2017, 20, 1359-1378.	1.4	4
18	Schedule 1 barriers to research in the UK: An in-depth qualitative analysis. <i>Drug Science, Policy and Law</i> , 2021, 7, 205032452110493.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation. American Journal of Bioethics, 2021, 21, 28-31.	0.5	1